NASDAQ:APENApollo Endosurgery Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apollo Endosurgery Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.59 -0.03 (-1.85 %) (As of 07/9/2020 10:55 AM ET) Add Compare Share Today's Range$1.59Now: $1.59▼$1.5950-Day Range$1.60MA: $1.83▼$2.2452-Week Range$1.24Now: $1.59▼$3.79Volume642 shsAverage Volume31,297 shsMarket Capitalization$33.72 millionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingApollo Endosurgery has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Apollo Endosurgery has a potential upside of 25.7% from its current price of $1.59.Amount of Analyst CoverageApollo Endosurgery has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesApollo Endosurgery has received 216 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApollo Endosurgery has received 186 “underperform” votes. (Add your “underperform” vote.)Community SentimentApollo Endosurgery has received 53.73% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote “Outperform” if you believe APEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApollo Endosurgery does not currently pay a dividend.Dividend GrowthApollo Endosurgery does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apollo Endosurgery insiders have not sold or bought any company stock.Percentage Held by Insiders37.20% of the stock of Apollo Endosurgery is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.00% of the stock of Apollo Endosurgery is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apollo Endosurgery are expected to grow in the coming year, from ($1.17) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apollo Endosurgery is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apollo Endosurgery is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApollo Endosurgery has a P/B Ratio of 15.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APEN Previous Symbol CUSIPN/A CIK1251769 Webwww.apolloendo.com Phone512-279-5100Debt Debt-to-Equity Ratio8.74 Current Ratio0.84 Quick Ratio0.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$50.71 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book15.91Profitability EPS (Most Recent Fiscal Year)($1.53) Net Income$-27,430,000.00 Net Margins-72.34% Return on Equity-565.93% Return on Assets-46.48%Miscellaneous Employees215 Outstanding Shares21,200,000Market Cap$33.72 million Next Earnings Date7/28/2020 (Estimated) OptionableNot Optionable NASDAQ:APEN Rates by TradingView Receive APEN News and Ratings via Email Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter. Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions How has Apollo Endosurgery's stock been impacted by COVID-19 (Coronavirus)? Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has decreased by 23.0% and is now trading at $1.5907. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Apollo Endosurgery? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Apollo Endosurgery. When is Apollo Endosurgery's next earnings date? Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Apollo Endosurgery. How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery Inc (NASDAQ:APEN) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.49) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.49). The biotechnology company had revenue of $10.72 million for the quarter, compared to analyst estimates of $9.07 million. Apollo Endosurgery had a negative return on equity of 565.93% and a negative net margin of 72.34%. View Apollo Endosurgery's earnings history. What price target have analysts set for APEN? 1 equities research analysts have issued 1-year price targets for Apollo Endosurgery's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Apollo Endosurgery's stock price to reach $2.00 in the next year. This suggests a possible upside of 25.7% from the stock's current price. View analysts' price targets for Apollo Endosurgery. Has Apollo Endosurgery been receiving favorable news coverage? Media headlines about APEN stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Apollo Endosurgery. Are investors shorting Apollo Endosurgery? Apollo Endosurgery saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 390,000 shares, a decrease of 10.8% from the May 31st total of 437,400 shares. Based on an average daily trading volume, of 18,100 shares, the days-to-cover ratio is presently 21.5 days. Currently, 3.2% of the company's stock are sold short. View Apollo Endosurgery's Current Options Chain. Who are some of Apollo Endosurgery's key competitors? Some companies that are related to Apollo Endosurgery include BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Venus Concept (VERO), PAVmed (PAVM), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Nephros (NEPH), Pro-Dex (PDEX), Nephros (NEPHD), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), Motus GI (MOTS) and Neuronetics (STIM). View all competitors. What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Tonix Pharmaceuticals (TNXP), Second Sight Medical Products (EYES), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Onconova Therapeutics (ONTX) and Opko Health (OPK). Who are Apollo Endosurgery's key executives? Apollo Endosurgery's management team includes the following people: Mr. Todd Newton, CEO & Director (Age 56)Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation PartnerMr. Anthony Kalloo M.D., Co-Founder and Innovation PartnerDr. Robert Hawes M.D., Co-Founder and Innovation PartnerDr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner What is Apollo Endosurgery's stock symbol? Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN." How do I buy shares of Apollo Endosurgery? Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Apollo Endosurgery's stock price today? One share of APEN stock can currently be purchased for approximately $1.59. How big of a company is Apollo Endosurgery? Apollo Endosurgery has a market capitalization of $33.72 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe. What is Apollo Endosurgery's official website? The official website for Apollo Endosurgery is www.apolloendo.com. How can I contact Apollo Endosurgery? Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected] This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
